AP2710A - Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors - Google Patents

Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors

Info

Publication number
AP2710A
AP2710A AP2009004790A AP2009004790A AP2710A AP 2710 A AP2710 A AP 2710A AP 2009004790 A AP2009004790 A AP 2009004790A AP 2009004790 A AP2009004790 A AP 2009004790A AP 2710 A AP2710 A AP 2710A
Authority
AP
ARIPO
Prior art keywords
pyrido
inhibitors
pyrimidinone compounds
pyrimidinone
compounds
Prior art date
Application number
AP2009004790A
Other languages
English (en)
Other versions
AP2009004790A0 (en
Inventor
Dilip Bhumralkar
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2009004790A0 publication Critical patent/AP2009004790A0/xx
Application granted granted Critical
Publication of AP2710A publication Critical patent/AP2710A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AP2009004790A 2006-09-15 2007-09-03 Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors AP2710A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30
PCT/IB2007/002578 WO2008032162A1 (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors

Publications (2)

Publication Number Publication Date
AP2009004790A0 AP2009004790A0 (en) 2009-04-30
AP2710A true AP2710A (en) 2013-07-30

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004790A AP2710A (en) 2006-09-15 2007-09-03 Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors

Country Status (42)

Country Link
US (3) US7696213B2 (es)
EP (1) EP2074122B9 (es)
JP (1) JP4718637B2 (es)
KR (1) KR101099926B1 (es)
CN (1) CN101573358B (es)
AP (1) AP2710A (es)
AR (1) AR062785A1 (es)
AT (1) ATE514695T1 (es)
AU (1) AU2007297212B8 (es)
BR (1) BRPI0716749B8 (es)
CA (1) CA2663401C (es)
CL (1) CL2007002682A1 (es)
CR (1) CR10662A (es)
CU (1) CU23783B7 (es)
CY (1) CY1111911T1 (es)
DK (1) DK2074122T5 (es)
DO (1) DOP2009000039A (es)
EA (1) EA016388B1 (es)
ES (1) ES2366489T3 (es)
GE (1) GEP20115306B (es)
GT (1) GT200700077A (es)
HK (1) HK1138589A1 (es)
HN (1) HN2007000267A (es)
HR (1) HRP20110621T2 (es)
IL (1) IL197243A (es)
MA (1) MA30709B1 (es)
ME (1) MEP8009A (es)
MX (1) MX2009002927A (es)
MY (1) MY146420A (es)
NI (1) NI200900032A (es)
NO (1) NO342357B1 (es)
NZ (1) NZ575167A (es)
PE (1) PE20080670A1 (es)
PL (1) PL2074122T3 (es)
PT (1) PT2074122E (es)
RS (2) RS51927B (es)
SI (1) SI2074122T1 (es)
TN (1) TN2009000085A1 (es)
TW (1) TWI334353B (es)
UY (1) UY30588A1 (es)
WO (1) WO2008032162A1 (es)
ZA (1) ZA200901477B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016388B1 (ru) 2006-09-15 2012-04-30 Пфайзер Продактс Инк. Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
AU2008236562B2 (en) * 2007-04-10 2013-11-07 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
NZ579945A (en) * 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
AU2009268469B2 (en) 2008-07-11 2013-02-28 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway
AU2009282571B2 (en) 2008-08-20 2014-12-11 Merck Sharp & Dohme Corp. Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734488A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5619743B2 (ja) * 2008-08-20 2014-11-05 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
TW201018685A (en) * 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
EP3053925A1 (en) 2010-12-16 2016-08-10 F. Hoffmann-La Roche AG Tricyclic pi3k inhibitor compounds and methods of use
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
EP2750675A1 (en) 2011-08-31 2014-07-09 Novartis AG Synergistic combinations of pi3k- and mek-inhibitors
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
AU2015296322B2 (en) 2014-07-26 2019-09-19 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as CDK inhibitors and uses thereof
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
JP6784668B2 (ja) 2014-10-10 2020-11-11 ファイザー・インク 相乗的オーリスタチン組合せ
PT3302565T (pt) 2015-06-04 2020-01-14 Pfizer Formas de dosagem sólida de palbociclib
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンThe Regents Of The University Of Michigan MEK/PI3K及びmTOR/MEK/PI3K生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
RS61934B1 (sr) 2016-08-15 2021-07-30 Pfizer Inhibitori piridopirimdinona cdk2/ 4/6
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
CN117843659A (zh) 2018-06-15 2024-04-09 詹森药业有限公司 雷帕霉素类似物和其用途
US20220220103A1 (en) * 2018-12-28 2022-07-14 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
WO2021139775A1 (zh) * 2020-01-10 2021-07-15 江苏先声药业有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
WO2022109001A1 (en) 2020-11-18 2022-05-27 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009993A1 (en) * 2001-12-11 2004-01-15 Pharmacia Italia S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
HUT76853A (en) 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
US20040224958A1 (en) 2000-01-27 2004-11-11 Booth Richard John Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
SK12472002A3 (sk) 2000-03-06 2003-04-01 Warner-Lambert Company 5-Alkylpyrido[2,3-d]pyrimidínové inhibítory tyrosínových kináz
ATE503743T1 (de) 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
SI1470124T1 (sl) 2002-01-22 2006-04-30 Warner Lambert Co 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-oni
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
US20050009849A1 (en) 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
DK1648889T3 (da) 2003-07-11 2009-01-05 Warner Lambert Co Isethionatsalt af en selektiv CDK4-inhibitor
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
BRPI0507668A (pt) 2004-02-14 2007-07-17 Irm Llc compostos e composições como inibidores de proteìna cinase
WO2005082903A1 (en) 2004-02-18 2005-09-09 Warner-Lambert Company Llc 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
JP5111113B2 (ja) 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
EA016945B1 (ru) * 2005-10-07 2012-08-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201200669A1 (ru) * 2005-10-07 2012-11-30 Экселиксис, Инк. ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EA016388B1 (ru) 2006-09-15 2012-04-30 Пфайзер Продактс Инк. Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
EP2134695A4 (en) * 2007-03-14 2011-05-25 Exelixis Inc HEMGE OF THE HEDGEHOG SIGNAL PATH
NZ579945A (en) 2007-04-11 2012-05-25 Exelixis Inc Pyrido [2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
TW201018685A (en) 2008-09-30 2010-05-16 Exelixis Inc Pyridopyrimidinone inhibitors of PI3Kα and mTOR
EP2557923A4 (en) * 2010-04-16 2013-10-23 Curis Inc TREATMENT OF CANCER DISORDERS WITH K-RAS MUTATIONS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009993A1 (en) * 2001-12-11 2004-01-15 Pharmacia Italia S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents

Also Published As

Publication number Publication date
DK2074122T5 (da) 2014-03-17
ZA200901477B (en) 2010-07-28
PT2074122E (pt) 2011-08-24
AU2007297212B8 (en) 2011-04-28
IL197243A0 (en) 2009-12-24
TW200820972A (en) 2008-05-16
RS20090104A (en) 2010-06-30
NI200900032A (es) 2010-05-14
IL197243A (en) 2013-07-31
NO342357B1 (no) 2018-05-14
NZ575167A (en) 2010-10-29
CU20090040A7 (es) 2011-07-11
HK1138589A1 (en) 2010-08-27
AU2007297212A1 (en) 2008-03-20
MEP8009A (en) 2011-12-20
WO2008032162A1 (en) 2008-03-20
MX2009002927A (es) 2009-03-31
US8273755B2 (en) 2012-09-25
GEP20115306B (es) 2011-10-10
EP2074122B1 (en) 2011-06-29
CN101573358B (zh) 2012-05-30
UY30588A1 (es) 2008-05-02
BRPI0716749A2 (pt) 2014-02-18
CR10662A (es) 2009-04-17
DOP2009000039A (es) 2015-12-15
KR20090040389A (ko) 2009-04-23
ATE514695T1 (de) 2011-07-15
CU23783B7 (es) 2012-02-15
US20120309775A1 (en) 2012-12-06
NO20091141L (no) 2009-03-31
RS51927B (en) 2012-02-29
AP2009004790A0 (en) 2009-04-30
JP4718637B2 (ja) 2011-07-06
US20080090801A1 (en) 2008-04-17
HN2007000267A (es) 2011-02-25
DK2074122T3 (da) 2011-08-15
CA2663401A1 (en) 2008-03-20
BRPI0716749B8 (pt) 2021-05-25
GT200700077A (es) 2009-08-03
CL2007002682A1 (es) 2008-04-04
US20100137279A1 (en) 2010-06-03
US8633204B2 (en) 2014-01-21
MY146420A (en) 2012-08-15
CN101573358A (zh) 2009-11-04
EA200970207A1 (ru) 2009-08-28
PE20080670A1 (es) 2008-06-14
US7696213B2 (en) 2010-04-13
AR062785A1 (es) 2008-12-03
ES2366489T9 (es) 2013-12-27
MA30709B1 (fr) 2009-09-01
TN2009000085A1 (fr) 2010-08-19
JP2010503653A (ja) 2010-02-04
ES2366489T3 (es) 2011-10-20
WO2008032162A8 (en) 2009-03-26
KR101099926B1 (ko) 2011-12-28
HRP20110621T1 (en) 2011-09-30
TWI334353B (en) 2010-12-11
PL2074122T3 (pl) 2011-10-31
CA2663401C (en) 2011-07-12
CY1111911T1 (el) 2015-11-04
BRPI0716749B1 (pt) 2020-10-06
EA016388B1 (ru) 2012-04-30
EP2074122B9 (en) 2013-09-11
SI2074122T1 (sl) 2011-10-28
AU2007297212B2 (en) 2011-04-14
HRP20110621T2 (hr) 2013-12-06
EP2074122A1 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
AP2710A (en) Pyrido (2, 3-D) Pyrimidinone compounds and their use as P13 inhibitors
SI1888580T1 (sl) Pirido d pirimidini uporabni kot inhibitorjiHCV in postopki za njihovo pripravo
IL210821A0 (en) Pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
IL198509A0 (en) Azaindole derivatives, compositions containing the same and uses thereof
AP2453A (en) Pyrazolo(3,4-B) pyridine derivatives as phosphodiesterase inhibitors
EP2154965A4 (en) NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
GB201000648D0 (en) Phosphodiesterase 10 inhibitors
ZA201004524B (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
IL210822A0 (en) Tri-cyclic pyrazolopyridine kinase inhibitor compounds, compositions comprising the same and uses thereof
SI1966202T1 (sl) S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
IL201009A0 (en) Pyrazolo pyridine derivatives, compositions comprising the same and uses thereof
SI1904494T1 (sl) Imidazo(1,2-a)piridin spojine kot inhibitorji vegf-r2
EP1732566A4 (en) 6-azaindole COMPOUND
IL201865A0 (en) Rna beta-catenin antagonist compounds, compositions comprising the same and uses thereof
ZA201005338B (en) Pyrrolo[2,3-d]pyridines and use thereof as tyrosine kinase inhibitors
SI1697356T1 (sl) Pirido(2,3-d)pirimidin-2,4-diamini kot zaviralci PDE 2
IL207452A0 (en) Pyrrolo pyrimidine derivatives, compositions comprising the same and uses thereof
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
IL202038A0 (en) Rna antagonist compounds, compositions comprising the same and uses thereof
EP2152080A4 (en) NEW SOLUBLE 1,4-BENZODIAZEPINE COMPOUNDS AND STABLE SALT THEREOF
HK1139948A1 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
ZA200904440B (en) 6-Benzyl-2,3,4,7-Tetrahydro-indolo [2,3-C] quinoline compounds useful as PDE5 inhibitors
IL190456A0 (en) Pyrazolo[4,3-d]pirimidin-5-yl)derivative used as pde5 inhibitors
GB0714815D0 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors